Publications
33
Citations
158
Est. group size
~8
Recurring co-author estimate
Active years
31
Publishing since 1996
Amir Yousif studies how immune cells called CD8+ T cells (a type of white blood cell that kills infected or cancerous cells) become dysfunctional or 'exhausted' during chronic infections and cancer, and how this process can be reversed to improve cancer immunotherapy. The work focuses on the molecular switches (such as proteins BLIMP1, KLF3, and KDM5A/B, and epigenetic changes—chemical modifications that control which genes are turned on or off) that control T cell memory and dysfunction, with applications to improving treatments like PD-1 blockade therapy.
Publication output was minimal or absent from 2017-2020, then increased modestly from 2021-2024, followed by a sharp surge in 2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- The transcriptional repressor BLIMP1 enforces TCF-1-dependent and -independent restriction of the memory fate of CD8+ T cells
Immunity · 2025
- Faithful modeling of terminal CD8+T cell dysfunction and epigenetic stabilization in vitro
JCI Insight · 2025
- Chronic ISG15 Exposure Accelerates CD8+ T-cell Dysfunction while Increasing PD-1 Blockade Sensitivity in Oral Squamous Cell Carcinoma
Cancer Immunology Research · 2025
- Faithful Modeling of Terminal CD8 T Cell Dysfunction and Epigenetic Stabilization <i>In Vitro</i>
bioRxiv (Cold Spring Harbor Laboratory) · 2025
- Figure S10 from Chronic ISG15 Exposure Accelerates CD8<sup>+</sup> T-cell Dysfunction while Increasing PD-1 Blockade Sensitivity in Oral Squamous Cell Carcinoma
2025
- Figure S2 from Chronic ISG15 Exposure Accelerates CD8<sup>+</sup> T-cell Dysfunction while Increasing PD-1 Blockade Sensitivity in Oral Squamous Cell Carcinoma
2025
- Figure S6 from Chronic ISG15 Exposure Accelerates CD8<sup>+</sup> T-cell Dysfunction while Increasing PD-1 Blockade Sensitivity in Oral Squamous Cell Carcinoma
2025
- Supplementary Table 2 from Chronic ISG15 Exposure Accelerates CD8<sup>+</sup> T-cell Dysfunction while Increasing PD-1 Blockade Sensitivity in Oral Squamous Cell Carcinoma
2025
- Figure S8 from Chronic ISG15 Exposure Accelerates CD8<sup>+</sup> T-cell Dysfunction while Increasing PD-1 Blockade Sensitivity in Oral Squamous Cell Carcinoma
2025
- Figure S9 from Chronic ISG15 Exposure Accelerates CD8<sup>+</sup> T-cell Dysfunction while Increasing PD-1 Blockade Sensitivity in Oral Squamous Cell Carcinoma
2025
- Supplementary Table 1 from Chronic ISG15 Exposure Accelerates CD8<sup>+</sup> T-cell Dysfunction while Increasing PD-1 Blockade Sensitivity in Oral Squamous Cell Carcinoma
2025
- Data from Chronic ISG15 Exposure Accelerates CD8<sup>+</sup> T-cell Dysfunction while Increasing PD-1 Blockade Sensitivity in Oral Squamous Cell Carcinoma
2025
- Figure S3 from Chronic ISG15 Exposure Accelerates CD8<sup>+</sup> T-cell Dysfunction while Increasing PD-1 Blockade Sensitivity in Oral Squamous Cell Carcinoma
2025
- Figure S1 from Chronic ISG15 Exposure Accelerates CD8<sup>+</sup> T-cell Dysfunction while Increasing PD-1 Blockade Sensitivity in Oral Squamous Cell Carcinoma
2025
- Figure S4 from Chronic ISG15 Exposure Accelerates CD8<sup>+</sup> T-cell Dysfunction while Increasing PD-1 Blockade Sensitivity in Oral Squamous Cell Carcinoma
2025
- The Journal of Immunology×8
- Nature Immunology×3
- Elsevier eBooks×2
- Nature×1
- Brain Behavior and Immunity×1
- Yi Wang
Medicine · The Ohio State University
- Hazem E. Ghoneim
Medicine · The Ohio State University
- Andreas Wieland
Medicine · The Ohio State University
- No‐Joon Song
Medicine · The Ohio State University
- Scott A. Hammond
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile